Dementia with Lewy bodies: emerging drug targets and therapeutics

References

• Hansen D, Ling H, Lashley T, et al. Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinson’s disease dementia. Neuropathol Appl Neurobiol. 2020 Jul 27;47(1):143–156. Epub ahead of print. PMID: 32720329.
   Web of Science ®Google Scholar
• Clinton LK, Blurton-Jones M, Myczek K, et al. Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30(21):7281–7289.
   PubMed Web of Science ®Google Scholar
• Aarsland D. Epidemiology and pathophysiology of dementia-related psychosis. J Clin Psychiatry. 2020 Sep 15;81(5):AD19038BR1C. PMID: 32936544.
   PubMed Web of Science ®Google Scholar
• Smirnov DS, Galasko D, Edland SD, et al. Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies. Neurology. 2020 May 19;94(20):e2076–e2087. Epub 2020 Apr 24. PMID: 32332125; PMCID: PMC7526670.
   PubMed Web of Science ®Google Scholar
• Matar E, Ehgoetz Martens KA, Halliday GM, et al. Clinical features of Lewy body dementia: insights into diagnosis and pathophysiology. J Neurol. 2020 Feb;267(2):380–389. Epub 2019 Oct 24. PMID: 31650254.
   PubMed Web of Science ®Google Scholar
• Palermo G, Del Prete E, Bonuccelli U, et al. Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between α-synucleinopathies. J Neurol. 2020 Jun 27:1–13. Epub ahead of print. PMID: 32594302; PMCID: PMC7320652. DOI:10.1007/s00415-020-09985-z.
   Web of Science ®Google Scholar
• Fayyad M, Majbour NK, Vaikath NN, et al. Generation of monoclonal antibodies against phosphorylated α-Synuclein at serine 129: research tools for synucleinopathies. Neurosci Lett. 2020 Apr 23;725:134899. Epub 2020 Mar 7. PMID: 32156613.
   PubMed Web of Science ®Google Scholar
• Brys M, Fanning L, Hung S, et al. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054. Mov Disord. 2019 Aug;34(8):1154–1163. Epub 2019 Jun 17. PMID: 31211448; PMCID: PMC6771554.
   PubMed Web of Science ®Google Scholar
• Farr SA, Roesler E, Niehoff ML, et al. Metformin improves learning and memory in the SAMP8 mouse model of Alzheimer’s disease. J Alzheimers Dis. 2019;68(4):1699–1710. PMID: 30958364.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao J, Guo FL, et al. Metformin ameliorates synaptic defects in a mouse model of AD by inhibiting Cdk5 activity. Front Cell Neurosci. 2020;14:170.
   PubMed Web of Science ®Google Scholar
• Tanokashira D, Kurata E, Fukuokaya W, et al. Metformin treatment ameliorates diabetes-associated decline in hippocampal neurogenesis and memory via phosphorylation of insulin receptor substrate 1. FEBS Open Bio. 2018;8(7):1104–1118.
   PubMed Web of Science ®Google Scholar
• Ryu YK, Go J, Park HY, et al. Metformin regulates astrocyte reactivity in Parkinson’s disease and normal aging. Neuropharmacol. 2020 Sep 15;175:108173. Epub 2020 Jun 1. PMID: 32497590.
   PubMed Web of Science ®Google Scholar
• McClean PL, Parthsarathy V, Faivre E, et al. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci. 2011 Apr 27;31(17):6587–6594. PMID: 21525299; PMCID: PMC6622662.
   PubMed Web of Science ®Google Scholar
• Duarte AI, Candeias E, Alves IN, et al. Liraglutide protects against brain amyloid-β1-42 accumulation in female mice with early Alzheimer’s disease-like pathology by partially rescuing oxidative/nitrosative stress and inflammation. Int J Mol Sci. 2020;21(5):1746. Published 2020 Mar 4.
   Web of Science ®Google Scholar
• Bomba M, Ciavardelli D, Silvestri E, et al. Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. Cell Death Dis. 2013;4(5):e612. Published 2013 May 2.
   PubMedGoogle Scholar
• An J, Zhou Y, Zhang M, et al. Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5×FAD mouse model of Alzheimer’s disease. Behav Brain Res. 2019;370:111932.
   PubMed Web of Science ®Google Scholar
• Athauda D, Maclagan K, Budnik N, et al. What effects might exenatide have on non-motor symptoms in Parkinson’s disease: a post Hoc analysis. J Parkinsons Dis. 2018;8(2):247–258.
   PubMedGoogle Scholar
• Trigiani LJ, Royea J, Lacalle-Aurioles M, et al. Pleiotropic benefits of the angiotensin receptor blocker candesartan in a mouse model of Alzheimer disease. Hypertension. 2018 Nov;72(5):1217–1226. PMID: 30354809.
   PubMed Web of Science ®Google Scholar
• Torika N, Asraf K, Apte RN, et al. Candesartan ameliorates brain inflammation associated with Alzheimer’s disease. CNS Neurosci Ther. 2018 Mar 24;24(3):231–242. Epub 2018 Jan 24. PMID: 29365370; PMCID: PMC6489976.
   PubMed Web of Science ®Google Scholar
• Hattori N, Takeda A, Takeda S, et al. Rasagiline monotherapy in early Parkinson’s disease: a phase 3, randomized study in Japan. Parkinsonism Relat Disord. 2019;60(Mar):146–152. Epub 2018 Sep 1. PMID: 30205936.
   PubMed Web of Science ®Google Scholar
• Song IU, Im JJ, Jeong H, et al. Possible neuroprotective effects of rasagiline in Alzheimer’s disease: a SPECT study. Acta Radiol. 2020 Jul 9:284185120940264. Epub ahead of print. PMID: 32646230. DOI:10.1177/0284185120940264.
   PubMed Web of Science ®Google Scholar
• Pagan FL, Hebron ML, Wilmarth B, et al. Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson disease: a phase 2 randomized clinical trial. JAMA Neurol. 2020 Mar 1;77(3):309–317. PMID: 31841599; PMCID: PMC6990742.
   PubMed Web of Science ®Google Scholar
• Hebron ML, Lonskaya I, Moussa CE. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson’s disease models. Hum Mol Genet. 2013;22(16):3315–3328.
   PubMed Web of Science ®Google Scholar
• Pagan F, Hebron M, Valadez EH, et al. Nilotinib effects in Parkinson’s disease and dementia with Lewy bodies. J Parkinsons Dis. 2016;6(3):503–517.
   PubMedGoogle Scholar
• Guttuso T Jr, Andrzejewski KL, Lichter DG, et al. Targeting kinases in Parkinson’s disease: a mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium. J Neurol Sci. 2019 Jul 15;402:121–130. Epub 2019 May 15. PMID: 31129265.
   PubMed Web of Science ®Google Scholar
• Lonskaya I, Hebron ML, Selby ST, et al. Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer’s disease models. Neuroscience. 2015 Sep 24;304:316–327. Epub 2015 Jul 30. PMID: 26235435.
   PubMed Web of Science ®Google Scholar
• Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013;54(4):683–687.
   PubMed Web of Science ®Google Scholar
• Valera E, Mante M, Anderson S, et al. Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson’s disease. J Neuroinflammation. 2015;12(1):93. Published 2015 May 14.
   PubMedGoogle Scholar
• Valera E, Spencer B, Fields JA, et al. Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy. Acta Neuropathol Commun. 2017;5(1):2. Published 2017 Jan 5.
   PubMedGoogle Scholar
• Decourt B, Wilson J, Ritter A, et al. MCLENA-1: a phase II clinical trial for the assessment of safety, tolerability, and efficacy of lenalidomide in patients with mild cognitive impairment due to Alzheimer’s disease. Open Access J Clin Trials. 2020;12:1–13.
   PubMed Web of Science ®Google Scholar
• Gocmez SS, Yazir Y, Gacar G, et al. Etanercept improves aging-induced cognitive deficits by reducing inflammation and vascular dysfunction in rats. Physiol Behav. 2020 Oct 1;224:113019. Epub 2020 Jun 20. PMID: 32569601.
   PubMed Web of Science ®Google Scholar
• Butchart J, Brook L, Hopkins V, et al. Etanercept in Alzheimer disease: a randomized, placebo-controlled, double-blind, phase 2 trial. Neurology. 2015 May 26;84(21):2161–2168. Epub 2015 May 1. Erratum in: Neurology. 2015 Dec 8;85(23):2084. PMID: 25934853; PMCID: PMC4451045.
   PubMed Web of Science ®Google Scholar
• Ciprés-Flores FJ, Segura-Uribe JJ, Orozco-Suárez S, et al. Beta-blockers and salbutamol limited emotional memory disturbance and damage induced by orchiectomy in the rat hippocampus. Life Sci. 2019 May 1;224:128–137. Epub 2019 Mar 21. PMID: 30905783.
   PubMed Web of Science ®Google Scholar
• Gronich N, Abernethy DR, Auriel E, et al. β2-adrenoceptor agonists and antagonists and risk of Parkinson’s disease. Mov Disord. 2018 Sep;33(9):1465–1471. PMID: 30311974.
   PubMed Web of Science ®Google Scholar
• Fois G, Hobi N, Felder E, et al. A new role for an old drug: ambroxol triggers lysosomal exocytosis via pH-dependent Ca2⁺ release from acidic Ca2⁺ stores. Cell Calcium. 2015 Dec;586:628–637. Epub 2015 Oct 27. PMID: 26560688.
   PubMed Web of Science ®Google Scholar
• Mullin S, Smith L, Lee K, et al. Ambroxol for the treatment of patients with Parkinson disease with and without Glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol. 2020;77(4):427–434.
   PubMed Web of Science ®Google Scholar
• Magalhaes J, Gegg ME, Migdalska-Richards A, et al. Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons. Sci Rep. 2018;8(1):1385.
   PubMedGoogle Scholar
• Yu JZ, Li YH, Liu CY, et al. Multitarget therapeutic effect of fasudil in APP/PS1 transgenic mice. CNS Neurol Disord Drug Targets. 2017;16(2):199–209. PMID: 27401064.
   PubMed Web of Science ®Google Scholar
• Gao Y, Yan Y, Fang Q, et al. The Rho kinase inhibitor fasudil attenuates Aβ1-42-induced apoptosis via the ASK1/JNK signal pathway in primary cultures of hippocampal neurons. Metab Brain Dis. 2019 Dec;346:1787–1801. Epub 2019 Sep 3. PMID: 31482248.
   PubMed Web of Science ®Google Scholar
• Elliott C, Rojo A, Ribe E, et al. A role for APP in Wnt signalling links synapse loss with β-amyloid production. Transl Psychiatry. 2018;8(1):179.
   PubMedGoogle Scholar
• Kramberger MG, Bjorn A, Garcia-Ptacek S, et al. Longitudinal cognitive decline in dementia with Lewy bodies in a large multi-center international cohort. J Alzheimers Dis. 2017;57(3):787–795.
   PubMed Web of Science ®Google Scholar